Pemigatinib Outperforms Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma : JCO | June 2026

Introduction:

Cholangiocarcinoma is an aggressive biliary tract malignancy with limited treatment options and poor long-term outcomes. The discovery of fibroblast growth factor receptor 2 (FGFR2) rearrangements in a subset of patients has transformed the therapeutic landscape, enabling the development of precision-targeted therapies. Pemigatinib previously demonstrated meaningful activity in previously treated FGFR2-rearranged cholangiocarcinoma, leading to its approval in the second-line setting.

Problem Statement:

Although targeted therapy has shown promise after chemotherapy failure, it remained uncertain whether FGFR inhibition could provide superior outcomes when used as first-line treatment. Establishing the role of precision medicine earlier in the disease course is critical for improving outcomes in biomarker-selected patients with advanced cholangiocarcinoma.

Summary:

The phase 3 FIGHT-302 trial represents the largest randomized study of a targeted therapy conducted in patients with advanced cholangiocarcinoma harboring FGFR2 rearrangements. The trial demonstrated that first-line pemigatinib significantly prolonged progression-free survival compared with standard gemcitabine-cisplatin chemotherapy. Pemigatinib also produced substantially higher objective response rates and more durable tumor responses, highlighting the effectiveness of biomarker-driven therapy in this molecularly defined population. Although overall survival was similar between treatment groups, interpretation is influenced by the study design, which allowed patients progressing on chemotherapy to receive pemigatinib subsequently. Notably, patients who crossed over to pemigatinib continued to derive meaningful clinical benefit, further supporting the activity of FGFR inhibition. The safety profile of pemigatinib was consistent with previous studies, with no unexpected toxicities identified. These findings provide strong evidence that molecular profiling should be routinely incorporated into the management of cholangiocarcinoma to identify patients with actionable FGFR2 alterations. The study marks an important milestone in biliary tract cancer, demonstrating that targeted therapy can outperform conventional chemotherapy in the frontline setting for appropriately selected patients. Overall, FIGHT-302 reinforces FGFR2 rearrangement as a clinically actionable biomarker and supports pemigatinib as a major therapeutic option in the evolving era of precision oncology for cholangiocarcinoma.